help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voordouw, B. C.
Right arrow Articles by Cohen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voordouw, B. C.
Right arrow Articles by Cohen, M.

Journal of Clinical Endocrinology & Metabolism, Vol 74, 108-117, Copyright © 1992 by Endocrine Society


ARTICLES

Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation

BC Voordouw, R Euser, RE Verdonk, BT Alberda, FH de Jong, AC Drogendijk, BC Fauser and M Cohen
Center for Reproductive Medicine and Breast Cancer Prevention, Dijkzigt University Hospital, Rotterdam, The Netherlands.

Although melatonin (MEL) controls seasonal reproductive cyclicity in some mammalian species, its role in women is controversial. In this study data are presented related to the influence of MEL or MEL- progestin combinations on the pituitary-ovarian axis and ovulation in 32 women. MEL was administered in a dosage of 300 mg to 12 women for 4 months [to 8 women daily (days 1-30) and to 4 women on days 5-17 of the cycle]. MEL was also combined with the synthetic progestin norethisterone (NET) in an attempt to evaluate MEL's effect on a partially suppressed pituitary-ovarian axis. In 16 women, 4 combinations were tested on 4 women each on days 1-21: dosages of 300 mg MEL/0.75 mg NET, 75 mg MEL/0.75 mg NET, 7.5 mg MEL/0.75 mg NET, and 75 mg MEL/0.30 mg NET. In addition, 2 women were medicated with 300 mg MEL alone, and 2 were medicated with 300 mg MEL/0.15 mg NET on days 1- 21 for 2 months. During the study, LH, FSH, estradiol (E2), and progesterone (P4) blood levels were determined at regular intervals. After a period of 4 months, daily administration of 300 mg MEL (days 1- 30) caused significantly decreased mean LH levels compared to those in 8 nonmedicated controls (P less than 0.001). Also compared to nonmedicated control data, a significant inhibition of P4 in the first and fourth medication months (P less than 0.001) was observed. LH and E2 inhibition reached significance in the fourth medication month (P less than 0.005). Also, the treatments of 300 mg MEL (days 5-17) and 75 mg MEL combined with 0.3 mg NET caused a significant decrease in LH, E2, and P4 levels compared to those in the nonmedicated control group in the first and fourth medication months (P less than 0.05). The data further suggest an additive or synergistic effect between MEL and NET. The medications did not alter sleep-wake rhythms and were not complicated by any side-effects. The presented data suggest that MEL and MEL/NET combinations inhibit ovarian function in women, and that MEL/NET combinations can emerge as effective oral contraceptives.


This article has been cited by other articles:


Home page
JCOHome page
Vijayalaxmi, C. R. Thomas Jr, R. J. Reiter, and T. S. Herman
Melatonin: From Basic Research to Cancer Treatment Clinics
J. Clin. Oncol., May 15, 2002; 20(10): 2575 - 2601.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Ishido, H. Nitta, and M. Kabuto
Magnetic fields (MF) of 50 Hz at 1.2 {micro}T as well as 100 {micro}T cause uncoupling of inhibitory pathways of adenylyl cyclase mediated by melatonin 1a receptor in MF-sensitive MCF-7 cells
Carcinogenesis, July 1, 2001; 22(7): 1043 - 1048.
[Abstract] [Full Text] [PDF]


Home page
Alcohol AlcoholHome page
R. G. Stevens and L. Hilakivi-Clarke
Alcohol exposure in utero and breast cancer risk later in life
Alcohol Alcohol., May 1, 2001; 36(3): 276 - 277.
[Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. Karbownik and R. J. Reiter
Antioxidative Effects of Melatonin in Protection Against Cellular Damage Caused by Ionizing Radiation
Experimental Biology and Medicine, October 1, 2000; 225(1): 9 - 22.
[Abstract] [Full Text]


Home page
Hum ReprodHome page
R. Luboshitzky, M. Levi, Z. Shen-Orr, Z. Blumenfeld, P. Herer, and P. Lavie
Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal men
Hum. Reprod., January 1, 2000; 15(1): 60 - 65.
[Abstract] [Full Text] [PDF]


Home page
J Biol RhythmsHome page
D. R. Weaver
Reproductive Safety of Melatonin: A "Wonder Drug" to Wonder About
J Biol Rhythms, December 1, 1997; 12(6): 682 - 689.
[Abstract] [PDF]


Home page
Endocr. Rev.Home page
B. C. J. M. Fauser and A. M. van Heusden
Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences
Endocr. Rev., February 1, 1997; 18(1): 71 - 106.
[Abstract] [Full Text]


Home page
NEJMHome page
A. Brzezinski
Melatonin in Humans
N. Engl. J. Med., January 16, 1997; 336(3): 186 - 195.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society